Br J Cancer: ALG5: Biomarker candidate for malignant slurry ovarian cancer

For a long time, the treatment strategy of advanced malignant slurry ovarian cancer (HGSOC) was a combination of cell reduction and platinum chemotherapy.
, although it can improve patient outcomes to some extent, a certain percentage of patients with complete excision (CGR) will relapse and die early.
the study aims to identify potential candidate biomarkers for HGSOC to help all patients develop personalized surgical treatments.
136 late HGSOC cases with CGR were identified from three common transcription set data sets in patients with advanced HGSOC tumors and improved prognostication.
identified the relevant candidate prognosmical biomarkers in the queue through Cox regression analysis and further validated them by targeting RNA sequencing in Imperial College Healthcare NHS Trust (n s 59) and HGSOC cases in open data sets.
finally explores the biological significance of candidate biomarkers through gene aquid analysis.
the biomarker identification process identified ALG5 as a prognostic biomarker for early tumor progression in patients with advanced HGSOC.
and further confirmed the prognosmical value of the new candidate biomarker in two separate data set.
mechanism studies have shown that oxidation phosphate has been shown to be a potential biological pathway mediated by high expression of ALG5 in patients with early recurrence.
relationship between ALG5 expression levels and prognosticity in HGSOC patients, the results revealed that ALG5 was an independent prognostic biomarker in patients with advanced HGSOC.
also lays a theoretical foundation for personalized surgery strategies in HGSOC patients.